焦作义

博士，教授，主任医师

电话：

+86-13893415219

传真：

0931-8458109

邮箱：

jiaozy@lzu.edu.cn

•荣誉奖励

2023                        甘肃省拔尖领军人才

2021                        甘肃省科技进步二等奖

2018                        甘肃省青年科技奖

2018                        甘肃省医学科技奖

2016                        甘肃省科技进步二等奖

2015                        甘肃省医学科技奖

•研究兴趣

围绕“靶免治疗时代如何提升消化系统肿瘤5年生存率”健康中国2030规划重大目标，聚焦“胃癌/胰腺癌耐药机制及新药研发”开展系统性研究。

•代表成果

1. Targeting UBE2T Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Regulating Pyrimidine Metabolism and Replication Stress. Jiang X, Ma Y, Wang T, Zhou H, Wang K, Shi W, Qin L, Guan J, Li L, Long B, Wang J, Guan X, Ye H, Yang J, Yu Z, Jiao Z*. Gastroenterology 2023, 164, 1232-1247.

2. PICH Activates Cyclin A1 Transcription to Drive S-Phase Progression and Chemoresistance in Gastric Cancer. Ye H, Shi W, Yang J, Wang L, Jiang X, Zhao H, Qin L, Qin J, Li L, Cai W, Guan J, Yang H, Zhou H, Yu Z, Sun H, Jiao Z*.   Cancer Res. 2023, 83, 3767-3782.

3. Therapeutic strategies targeting uPAR potentiate anti-PD-1 efficacy in diffuse-type gastric cancer. Qin L, Wang L, Zhang J, Zhou H, Yang Z, Wang Y, Cai W, Wen F, Jiang X, Zhang T, Ye H, Long B, Qin J, Shi W, Guan X, Yu Z, Yang J, Wang Q, Jiao Z*. Sci. Adv. 2022, 8, eabn3774.

4. Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer.  Shi W, Zhang G, Ma Z, Li L, Liu M, Qin L, Yu Z, Zhao L, Liu Y, Zhang X, Qin J, Ye H, Jiang X, Zhou H, Sun H, Jiao Z*. Nat. Commun. 2021, 12, 2812.

5. A novel UBE2T inhibitor suppresses Wnt/β-catenin signaling hyperactivation and gastric cancer progression by blocking RACK1 ubiquitination. Yu Z, Jiang X, Qin L, Deng H, Wang J, Ren W, Li H, Zhao L, Liu H, Yan H, Shi W, Wang Q, Luo C, Long B, Zhou H, Sun H, Jiao Z*. Oncogene 2021, 40, 1027-1042.